PERIPHERAL BLOOD LYMPHOCYTES PHENOTYPIC COMPOSITION IN PATIENTS WITH CERVICAL PAPILOMAVIRUS INFECTIONS, WHICH IgG ANTIBODY TO HERPES SIMPLE VIRUSES WERE DETERMINED
DOI:
https://doi.org/10.11603/1681-2727.2018.2.9033Keywords:
papillomaviruses, herpesviruses, cervix, lymphocytes, natural killer, peripheral blood.Abstract
The aim of the work – to determine the phenotypic composition of peripheral blood lymphocytes in patients with cervical papillomavirus infection (PVI), whose blood serum showed IgG antibodies to herpes simplex viruses with (HSV)-I and/or (HSV)-2.
Materials and methods. 43 women (average age 26.5 years old) with human papillomavirus (HPV)-induced cervical papillomavirus infection diseases diagnosed by molecular-biological, colposcop, and cytological methods of examination were inspected. Serum screening for anti-HSV-1 and anti-HSV-2 IgG as well as examination of anti-HSV-2 IgG avidity index were examined by solid-phase enzyme-linked immunosorbent assay. The phenotypic composition of peripheral blood lymphocytes were examined by the flow cytofluorometry method using monoclonal antibodies (Beckman Coulter, USA) to CD3+, CD4+, CD8+, CD3+/HLA-DR+, CD3+/CD16+/€D56+, CD4+45RA+ CD16+/CD56+/CD8+ and CD16+/CD56+ antigens. The count of cells and data analysis were performed by cytofluormeter FC-500 (Beckman Coulter, США). The count of cells and analysis of the results were performed by cytofluormeter i. IgG antibodies to HSV-1, HSV-2 or to these two viruses in serum of patients with cervical PVI were detected in 90.0 % of cases, in which the clinical symptoms of herpetic infection were no identificated. IgG antibodies to HSV-2 in serum of patients had only mean or low avidity. In patients with IgG antibodies to HSV-2 or simultaneously with HSV-2 and HSV-1, and, above all, with low- avidity IgG antibodies to HSV-2 the frequency of HPV-induced cervical intraepithelial neoplasia (CIN) of І-ІІ and ІІІ grade and cancer in situ was increased. The number of CD3+, CD4+, CD8+, CD4+45RA+ аnd CD16+/CD56+ cells in the patients’ peripheral blood, as well as the CD4+/CD8+ index were not altered compared to the indicators for clinically healthy subjects (control). But the tendency to increase the number of CD16+/CD56+/CD8+ cells, as well as a significant increase in the number of СD3+/HLA-DR+ cells were determined. The number of CD3+/CD16+/CD56+ cells was reduced in peripheral blood of patients with low-avidity of IgG antibodies to HSV-2, whereas in the remaining patients it was at the control level. meter FC-500 (Beckman Coulter, USA).
Results and discussion. In patients serum with CU HPVI without clinical signs of herpetic infection to HSV-1, HSV-2 IgG antibodies, both these two viruses simultaneously were diagnosed in 90.0 % of cases. Anti-HSV-2 IgG in patients’ serum had only medium or low avidity. The frequency of revealing HPV-induced cervical intraepithelial neoplasia (CIN) I-ІІ and ІІІ degree of activity, and cancer in situ increased in patients with anti-HSV-2 IgG or simultaneously to anti-HSV-1 and anti-HSV-2 but, first of all, in patients with low avidity anti-HSV-2 IgG. The number of CD3+, CD4+, CD8+, CD4+45RA+ and CD16+/CD56+ cells in the patients’ peripheral blood, as well as CD4+/CD8+ index did not change as compared with group of clinically healthy persons (control group). However, there was determined the tendency of CD16+/CD56+/CD8+ cells number increase and significant СD3+/HLA-DR+ cells number increase. CD3+/CD16+/CD56+ cells number in peripheral patients’ blood with low avidity to anti-HSV-2 IgG antibodies was reduced whereas it was equal to control level in the rest patients.
Conclusion. In patients with CU HPVI without clinical manifestation of herpetic infection anti-HSV-2 low avidity IgG were identified. The frequency of more severe CIN cause was increased. There were more significant displacement of cell immunity confirmed by CD3+/HLA-DR+ cells number increase and tendency of CD16+/56+CD8+ cells number increase, too, on the background of СD3+/CD16+/CD56+ cytotoxic T-lymphocytes decrease. Complex individual treatment of these patients with anti-herpetic drugs must probably be used.
References
Christensen, N.D. (2016). HPV disease transmission protection and control. Microbial Cell, 3(9), 476-490. doi: 10.15698/mic2016.09.530.
Hus, I., Gonet-Sebastianka, J., Surdacka, A., Bojarska-Junak, A., Roliński, J. (2015). Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine. Postepy Hig. Med. Dosw. (Online), 28(69), 543-548. doi: 10.5604/17322693.1150785.
Shanmugasundaram, S., & You, J. (2017). Targeting persistent human papillomavirus infection. Viruses, 9 (8), pii: E229. doi: 10.3390/v9080229.
Lazarenko, L.M., Nikitina, O.E., Nikitin, E,V., Demchenko, O.M., Kovtonyuk, G.V., Ganova, … & M.Ya. (2014). Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions. The EPMA J., 5(1), 1. doi:10.1186/1878-5085-5-1PMCID: PMC3901026
Graham, S.V. (2017). Keratinocyte Differentiation-Dependent Human Papillomavirus Gene Regulation. Viruses, 9 (245). pii: E245. doi: 10.3390/v9090245.
Deligeoroglou, E., Giannouli, A., Athanasopoulos, N., Karountzos, V., Vatopoulou, A., Dimopoulos, K., & Creatsas, G. (2013). HPV infection: immunological aspects and their utility in future therapy. Infectious Diseases in Obstetrics and Gynecology, (9), 540850. doi: 10.1155/2013/540850.
Cladel, N.M., Bertotto, A., Christensen, N.D. (2010). Human alpha and beta papillomaviruses use different synonymous codon profiles. Virus Genes, 40(3), 329-340. doi: 10.1007/s11262-010-0451-1.
Song, D., Li, H., Li, H., Dai J. (2015). Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer. Oncology Letters, 10 (2), 600-606. doi:10.3892/ol.2015.3295.
Guidry, J.T., Scott, R.S. (2017). The interaction between human papillomavirus and other viruses. Virus Research, 231, 139-147. doi: 10.1016/j.virusres.2016.11.002.
Frazer, I.H. (2009). Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology, 384, 410-414. doi: 10.1016/j.virol.2008.10.004.
Colmenares, V., Noyola, D.E., Monsiváis-Urenda, A., Salgado-Bustamante, M., Estrada-Capetillo, L., González-Amaro, R., & Baranda, L. (2009). The influence of human papillomavirus type and HIV status on the lymphomononuclear cell profile in patients with cervical intraepithelial lesions of different severity. Infectious Agents and Cancer, 4 (11), 1005-11. doi: 10.1128/CVI.00043-12.
Senba, M., Mori, N. (2012). Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. Oncology Rev., 6, e17. doi: 10.4081/oncol.2012.e17.
Skeate, J.G., Porras, T.B., Woodham, A.W., Jang, J.K., Taylor, J.R., Brand, H.E., … & Kast, W.M. (2012). Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. Clinical and Vaccine Immunology, 19 (7), 1005-1011. doi: 10.1128/CVI.00043-12.
Jaishankar, D., Shukla, D. (2016). Genital Herpes: Insights into Sexually Transmitted Infectious Disease. Microbial Cell, 3(9), 438-450. doi: 10.15698/mic2016.09.528.
Bedoui, S., Heath, W.R., & Mueller, S.N. (2016). CD4(+) T-cell help amplifies innate signals for primary CD8(+) T-cell immunity. Immunological Rev., 272, 1, 52-64. doi: 10.1111/imr.12426.
Sauerbrei, A. (2016). Herpes genitalis: Diagnosis, treatment and prevention. Geburtshilfe Frauenheilkd, 76 (12), 1310-1317. doi: 10.1055/s-0042-116494.
Da Silva, D.M., Woodham, A.W., Skeate, J.G., Rijkee, L.K., Taylor, J.R., Brand, H.E., … & Kast, W.M. (2015). Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clinical Immunology, 161 (2), 197-208. doi: 10.1016/j.clim.2015.09.003.
Handisurya, A., Day, P.M., Thompson, C.D., Bonelli, M., Lowy, D.R., Schiller, J.T. (2014). Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1. PLoS Pathogens, 10 (8), e1004314. doi: 10.1371/journal.ppat.1004314.
Pita-Lopez, M.L., Ortiz-Lazareno, P.C., Navarro-Meza, M., Santoyo-Telles, F., Peralta-Zaragoza, O. (2014). CD28-, CD45RA(null/dim) and natural killer-like CD8+ T cells are increased in peripheral blood of women with low-grade cervical lesions. Cancer Cell International, 14 (1), 97. doi: 10.1186/s12935-014-0097-5.
Visser, J., Nijman, H.W., Hoogenboom, B.N., Jager, P., van Baarle, D., Schuuring, E., … & Daemen, T. (2007). Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clinical & Experimental Immunology, 150 (2), 199-209. doi:10.1111/j.1365-2249.2007.03468.x.
Pievani, A., Borleri, G., Pende, D., Moretta, L., Rambaldi, A., Golay J., … & Introna M. (2011). Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood, 118(12), 3301-3310. doi: 10.1182/blood-2011-02-336321.
Colmenares, V., Noyola, D.E., Monsiváis-Urenda, A., Salgado-Bustamante, M., Estrada-Capetillo L., González-Amaro, R., & Baranda, L. (2012). Human papillomavirus immunization is associated with increased expression of different innate immune regulatory receptors. Clinical and Vaccine Immunology, 19 (7), 1005-1011. doi: 10.1128/CVI.00043-12.
Downloads
Published
How to Cite
Issue
Section
License
Автори, які публікуються у цьому журналі, погоджуються з наступними умовами:
- Автори залишають за собою право на авторство своєї роботи та передають журналу право першої публікації цієї роботи, яка через [ВКАЖІТЬ ПЕРІОД ЧАСУ] з дати публікації автоматично стає доступною на умовах ліцензії Creative Commons Attribution License, котра дозволяє іншим особам вільно розповсюджувати опубліковану роботу з обов'язковим посиланням на авторів оригінальної роботи та першу публікацію роботи у цьому журналі.

- Автори мають право укладати самостійні додаткові угоди щодо неексклюзивного розповсюдження роботи у тому вигляді, в якому вона була опублікована цим журналом (наприклад, розміщувати роботу в електронному сховищі установи або публікувати у складі монографії), за умови збереження посилання на першу публікацію роботи у цьому журналі.
Політика журналу дозволяє і заохочує розміщення авторами в мережі Інтернет (наприклад, у сховищах установ або на особистих веб-сайтах) рукопису роботи, як до подання цього рукопису до редакції, так і під час його редакційного опрацювання, оскільки це сприяє виникненню продуктивної наукової дискусії та позитивно позначається на оперативності та динаміці цитування опублікованої роботи (див. The Effect of Open Access).
Accepted 2018-05-30
Published 2018-06-15